| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.24 | 9e-07 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.15 | 1e-06 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.13 | 3e-05 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0003 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.25 | 0.0006 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0006 |